Induction of Erythroid Differentiation in Human Erythroleukemia Cells by Depletion of Malic Enzyme 2
Open Access
- 2 September 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (9), e12520
- https://doi.org/10.1371/journal.pone.0012520
Abstract
Malic enzyme 2 (ME2) is a mitochondrial enzyme that catalyzes the conversion of malate to pyruvate and CO2 and uses NAD as a cofactor. Higher expression of this enzyme correlates with the degree of cell de-differentiation. We found that ME2 is expressed in K562 erythroleukemia cells, in which a number of agents have been found to induce differentiation either along the erythroid or the myeloid lineage. We found that knockdown of ME2 led to diminished proliferation of tumor cells and increased apoptosis in vitro. These findings were accompanied by differentiation of K562 cells along the erythroid lineage, as confirmed by staining for glycophorin A and hemoglobin production. ME2 knockdown also totally abolished growth of K562 cells in nude mice. Increased ROS levels, likely reflecting increased mitochondrial production, and a decreased NADPH/NADP+ ratio were noted but use of a free radical scavenger to decrease inhibition of ROS levels did not reverse the differentiation or apoptotic phenotype, suggesting that ROS production is not causally involved in the resultant phenotype. As might be expected, depletion of ME2 induced an increase in the NAD+/NADH ratio and ATP levels fell significantly. Inhibition of the malate-aspartate shuttle was insufficient to induce K562 differentiation. We also examined several intracellular signaling pathways and expression of transcription factors and intermediate filament proteins whose expression is known to be modulated during erythroid differentiation in K562 cells. We found that silencing of ME2 leads to phospho-ERK1/2 inhibition, phospho-AKT activation, increased GATA-1 expression and diminished vimentin expression. Metabolomic analysis, conducted to gain insight into intermediary metabolic pathways that ME2 knockdown might affect, showed that ME2 depletion resulted in high orotate levels, suggesting potential impairment of pyrimidine metabolism. Collectively our data point to ME2 as a potentially novel metabolic target for leukemia therapy.Keywords
This publication has 69 references indexed in Scilit:
- Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemiaBlood, 2009
- Ezetimibe Is an Inhibitor of Tumor AngiogenesisThe American Journal of Pathology, 2009
- Nuclear translocation of active AKT is required for erythroid differentiation in erythropoietin treated K562 erythroleukemia cellsThe International Journal of Biochemistry & Cell Biology, 2009
- Differential Contribution of the Gata1 Gene Hematopoietic Enhancer to Erythroid DifferentiationMolecular and Cellular Biology, 2009
- Disruption of Mitochondrial Malate-Aspartate Shuttle Activity in Mouse Blastocysts Impairs Viability and Fetal Growth1Biology of Reproduction, 2009
- UCP2 Modulates Cell Proliferation through the MAPK/ERK Pathway during Erythropoiesis and Has No Effect on Heme Biosynthesis*Published by Elsevier BV ,2008
- ROS and p53: A versatile partnershipFree Radical Biology & Medicine, 2008
- IQGAP1 modulates activation of B-RafProceedings of the National Academy of Sciences of the United States of America, 2007
- The Putative Morphogen, DIF-1, of Dictyostelium discoideum Activates Akt/PKB in Human Leukemia K562 CellsBiochemical and Biophysical Research Communications, 1999
- Malic enzyme and malate dehydrogenase activities in rat tracheal epithelial cells during the progression of neoplasiaCancer Letters, 1985